Articles tagged with Chemotherapy
The National Cancer Institute has issued a clinical announcement recommending a combination of chemotherapy regimens for women with advanced ovarian cancer. The treatment involves delivering chemotherapy directly into the abdominal cavity (intraperitoneal, or IP) in addition to traditional IV chemotherapy. This approach appears to be m...
A new study confirms the survival benefit of intra-abdominal chemotherapy, also known as intraperitoneal (IP) chemotherapy, for most women with advanced ovarian cancer. The treatment has shown an overall survival period of approximately one year after optimal debulking surgery.
A new study found that hearing loss from chemotherapy is common in children treated with platinum agents, with 61% of patients experiencing some form of hearing loss. The study highlights the need for improved reporting and awareness of ototoxicity to prevent long-term development issues.
A Phase 3 study found that Aranesp treatment achieved and maintained target hemoglobin levels, reducing red blood cell transfusions by 24%. The extended dosing schedule may allow physicians to treat anemia on the same schedule as chemotherapy.
A new study by BCIRG shows that Herceptin paired with chemotherapy significantly improves disease-free survival in early breast cancer patients, while eliminating cardiac toxicity. The treatment also reduces the risk of relapse by 51% and is an alternative to standard therapy for patients at risk of heart damage.
A pilot study found that pairing low-dose chemotherapy with the anti-VEGF antibody bevacizumab delayed breast cancer progression by an average of 5.5 months compared to low-dose chemotherapy alone. The combination therapy showed better results, with 29% partial responses and 41% stable disease.
Chemotherapy has been shown to improve survival rates for patients with advanced colon cancer, regardless of age or sex. The study found that women and the elderly received the same benefit as younger adults, but were less likely to receive chemotherapy treatment.
A randomized clinical trial of dose-dense chemotherapy in early-stage breast cancer found the regimen to be safe, with a 13% reduced risk of death. However, the dose-dense treatment increased acute toxic effects such as anemia and bone pain, but these were mild and easy to manage.
The use of chemotherapy after surgery for stage III colon cancer has increased, leading to improved 5-year survival rates. Adjuvant chemotherapy benefits younger and elderly patients equally, while black patients with high-grade cancers see less significant improvements.
Researchers found that chemotherapy with doxorubicin and cisplatin extended disease-free survival by 50% and overall survival by 13% compared to radiation therapy. Serious side effects were more common in the chemotherapy group, but a new regimen may be less toxic.
A recent study published in The Lancet suggests that high-dose chemotherapy improves both event-free and overall survival for women with advanced breast cancer. This finding contradicts previous studies, highlighting the need for further investigation into this treatment strategy.
Researchers at Thomas Jefferson University discover fullerene nanoparticle reduces organ damage from ionizing radiation by one-half to two-thirds, outperforming current protection methods. The agent also provides specific protection for organs like the kidney and nervous system.
Researchers developed a genetic profile of ovarian cancer that predicts survival and identifies key genes involved in chemotherapy response. The study used microarray analysis to identify a gene expression profile known as the Chemotherapy Response Profile, which confirms the importance of genes such as BAX.
ECCO 13 study investigates post-treatment parenthood success rates in Hodgkin's lymphoma patients, with radiotherapy and chemotherapy linked to higher pregnancy success. The research highlights the importance of preserving fertility in young cancer survivors.
A combination treatment of Xeloda and oxaliplatin (XELOX) has been shown to reduce hospital visits by over 60% in patients with early colon cancer. This results in more time for patients to spend with family and return to work, improving their quality of life.
A new study found that a vitamin D pill combination extended the lives of men with advanced prostate cancer by about eight months compared to those receiving chemotherapy and placebo. The pill, DN-101, also protected against major side effects of chemotherapy.
New therapy Iressa shows no significant survival improvement for NSCLC patients, but offers better outcomes for Asian and non-smoking patients. The study results provide insight into the effectiveness of EGFR inhibitors in specific patient groups.
Researchers analyzed medication orders from outpatient clinics and found a three percent overall error rate and two percent serious error rate. Most errors were due to omitted dosages or incorrect orders, but serious harm was avoided by existing checks in most cases.
Researchers found that 3% of medication orders contained errors, with 60% of pediatric errors and 82% of adult errors having potential to harm patients. Hospitals implemented changes to their automated drug order-entry systems to reduce future errors.
The HERA study found that Herceptin reduces the risk of cancer coming back by 52% and death by 33% in early-stage HER2-positive breast cancer. The results provide new hope for women with this aggressive form of breast cancer, offering improved survival rates.
The Herceptin trial showed a significant reduction in disease recurrence in women with aggressive HER2-positive breast cancer. The treatment improved disease-free survival and overall outcomes, with no serious cardiac side effects reported.
Researchers discovered that endothelial cells lack the transport protein used by tumours to eject foreign molecules, making them vulnerable to anti-cancer drug GSAO. This breakthrough could lead to more effective treatment strategies against various tumour types.
A clinical trial has found that a new treatment regimen combining radiation therapy with concurrent chemotherapy significantly increases the probability of survival for patients with recurrent squamous-cell head and neck cancer. The study showed improved one-year and two-year survival rates compared to standard chemotherapy treatment, ...
Combining chemotherapy with radiation therapy before surgery improves local tumor control and reduces cancer return rates. The study, published by the American Society for Radiation Oncology, suggests this treatment should be recommended for most rectal cancer patients.
A Columbia University study reveals that black women with early-stage breast cancer are two times more likely to die within five years after diagnosis compared to white women. The study found that only 68% of black patients completed all prescribed chemotherapy cycles, compared to 76% of white patients.
A pilot study at Michigan State University found reflexology to be the most effective complementary therapy for women receiving chemotherapy for late-stage breast cancer. Reflexology applied firm pressure to certain parts of the foot helped reduce depression, anxiety, and improved spirituality and emotional quality of life.
A study by Yale researchers found that a combination of platinum-based chemotherapy and vaginal radiation significantly reduces the recurrence of uterine papillary serous carcinoma (UPSC). The procedure increases survival rates among women with this aggressive form of uterine cancer, which affects about seven percent of new cases at Yale.
Researchers found that the drug combination increased stem cell mobilization in 25 patients, reducing the number of necessary stem cell collections. This can lead to more successful transplantations and faster recovery for cancer patients.
Researchers discover Chk1 protein plays natural defense against therapeutic damage in cancer cells, making treatment less effective. Combining chemotherapy agents with Chk1 inhibitors may increase efficacy and overcome clinical resistance.
Researchers at Thomas Jefferson University found that giving chemotherapy and radiation together from the start may help patients with locally advanced lung cancer live longer. The study compared three treatment approaches and showed that combining chemotherapy and radiation improved patient outcomes.
Researchers develop stealth particles to deliver chemotherapy drugs to tumors, reducing phagocytosis by 24% in cell culture. The system allows for targeted delivery of lower doses, potentially improving cancer treatment outcomes.
Research finds that neutropenia, a type of hematological toxicity, is associated with increased overall survival in patients with advanced non-small cell lung cancer. Prospective trials are needed to assess whether drug dosing guided by toxic effects could improve chemotherapy efficacy.
Researchers at Children's National Medical Center discovered a non-toxic chemical compound OGT2378 that blocks ganglioside production, suppressing tumor growth and immune system suppression. The study found tumors in treated mice to be significantly smaller than those in untreated mice.
A study found that high-dose anticancer chemotherapy and total body irradiation can cause a lack of permanent teeth and microdontia in children. The study, conducted by Päivi Hölttä, suggests that these treatments can have long-term effects on dental development.
A recent study has found that obese patients with estrogen-receptor negative (ER-negative) breast cancer are at risk of undertreatment due to reduced chemotherapy doses. The study, published in The Lancet, suggests that obese women with ER-negative disease who receive 85% or more of the recommended first course dose have significantly ...
Researchers identified 57 predictor genes that can accurately predict breast cancer patients' response to chemotherapy, offering a powerful tool for personalized treatment. These genetic markers can identify patients most likely to benefit from chemotherapy, potentially shifting focus away from standard treatments.
A team of UW-Madison scientists has developed a technique to easily manipulate and exchange the sugars found in chemicals produced in nature. This breakthrough could lead to the development of new anti-cancer treatments by allowing researchers to rapidly scan the roles of different sugars in complex natural products.
A randomised trial found that blood stem cell transplant improved disease-free survival in children with high-risk acute lymphoblastic leukaemia, compared to chemotherapy. The study showed a significant gap between the two strategies as patient risk profiles worsened.
Researchers design dual-chamber nanocell to deliver anti-angiogenic and chemotherapy drugs to tumors, reducing toxicity and improving survival rates. The new approach shows great potential in treating two types of cancers, with mice surviving up to 65 days without severe side effects.
A new study suggests that PET imaging can identify which breast cancer patients are likely to respond to chemotherapy, allowing for more effective treatment and improved patient outcomes. This breakthrough could lead to the development of personalized treatment plans, giving patients and doctors more options.
A new study suggests that men over 50 with unexplained ataxia or tremors should undergo testing to check if they have the FMR1 gene, which causes Fragile X-related disorder. The guidelines were developed after a multi-center study found 56 people had received prior diagnoses of other conditions before being correctly diagnosed with FXTAS.
A recent study published in The Lancet found that a single dose of chemotherapy is comparable to radiotherapy in treating stage 1 seminoma. Patients who received chemotherapy had fewer seminomas occurring in their remaining testicle and were less likely to develop tumors.
Researchers identify HPV types 16 and 18 as key factors in cervical precancer development, supporting targeted management for high-risk women. Night-shift work linked to increased breast cancer risk, while melatonin levels found to lower risk.
Researchers discovered that griseofulvin inhibits cancer cell growth by affecting mitosis, potentially providing a therapeutic advantage when combined with other treatments. The drug has been used for decades to treat fungal infections and shows mild anti-cancer activity.
A large study comparing thalidomide and traditional chemotherapy in multiple myeloma patients found that thalidomide was more effective, with 76% of patients achieving at least partial remission. The treatment also had fewer side effects, particularly deep vein thrombosis compared to granulocytopenia.
Researchers from Munich discovered that sequential FDG-PET can identify responding tumors after just one cycle of chemotherapy, allowing for earlier assessment of treatment efficacy. This could lead to more accurate individualized treatment and improved patient outcomes.
Researchers have made advances in nuclear medicine, providing alternatives to traditional chemotherapy treatment for non-Hodgkin's lymphoma patients. The new treatments showed improved response rates and durations, exceeding those following chemotherapy, and offer a personalized dose option.
Researchers at Michigan Medicine have developed a nanoparticle-based treatment that targets cancer cells, increasing therapeutic response and reducing drug toxicity. The treatment uses dendrimers to deliver methotrexate and folate, allowing the cancer cells to internalize the drugs while minimizing harm to normal cells.
Researchers found that a vaccine targeting TRP-2 improves chemotherapy sensitivity in brain tumors. The study showed significant improvements in patient survival and tumor response rates compared to conventional treatments.
A cancer drug has been found to control levels of a hormone receptor protein in the womb, which is linked with giving birth. The study, funded by Action Medical Research, aims to assess whether the drug can be used to prevent premature birth.
Research suggests that obese women with breast cancer are more likely to receive reduced doses of adjuvant chemotherapy, leading to poorer outcomes. The study analyzed data from 9,672 women and found that 37% of severely obese patients received a dose reduction of at least 10%, compared to 20% of obese patients.
Researchers found that women who exercised during and after chemotherapy had improved activated lymphocytes and reduced inflammation. The exercise program improved physical functions and overall quality of life compared to non-exercisers.
A 14-month study found that dexmethyphenidate (d-MPH) significantly reduced fatigue and improved memory in cancer survivors with chemobrain. The medication, taken at dosages of 10-50 mg per day, showed safe and effective results for relieving chemobrain symptoms.
A new study finds that oral capecitabine plus oxaliplatin shows comparable efficacy and toxicity profiles to traditional intravenous chemotherapy, offering a more convenient treatment option for patients. The regimen has shown similar response rates and overall survival, with benefits in terms of patient autonomy and quality of life.
Researchers identified genetic variations associated with treatment resistance in childhood ALL, highlighting potential for personalized chemotherapy and simplified diagnostic tests. The study found links between specific gene variants and hematological relapse and central nervous system (CNS) cancer recurrence.
Researchers studied the combination of S-1, a new drug, and cisplatin in patients with advanced gastric cancer. Overall, 65% of patients responded to the chemotherapy, showing tumors shrunk in response to the drug.
A randomized multicenter study found that the doxorubicin-docetaxel combination is associated with an increased risk of severe sepsis and life-threatening complications in breast cancer patients. The incidence of febrile neutropenia was significantly higher with this regimen, resulting in 2 deaths related to drug toxicity.
Researchers found a risk of cardiac toxicity ranging from 2.2 to 3.3 percent among patients receiving chemotherapy and trastuzumab. The study documented less than 1 percent of patients experiencing heart muscle damage alone during chemotherapy.
A large community-based clinical trial showed a significant reduction in febrile neutropenia and chemotherapy dose reductions among older patients receiving Neulasta. The study found that Neulasta reduced the incidence of serious adverse events, including hospitalizations and pneumonia.
Researchers have developed a new treatment called RADPLAT, which combines radiation and cisplatin delivered directly to the tumor via tiny catheters. This approach has shown encouraging results in patients with advanced stage IV-T4 disease, with high rates of local and regional tumor control and overall survival.